FDA approves new use for latest Lilly blockbuster Cymbalta
Fort Wayne News-Sentinel - The drugmaker announced Monday that the FDA approved Cymbalta for the treatment of generalized anxiety disorder, a mental illness marked by chronic anxiety, irritability and fatigue, among other symptoms. More than 6 million Americans have the
Source: www.fortwayne.com
MediciNova Initiates Phase II Clinical Trial for MN-305, a Novel
PrimeZone - HT1A receptor under development both for the treatment of insomnia as well as for anxiety disorders such as Generalized Anxiety Individuals suffering from insomnia exhibit at least one of the following symptoms: - difficulty falling asleep (sleep
Source: www.primezone.com
Click here for more information about anxiety attacks paper bag
<< Home